PR Newswire Clinical TrialsOriginal article
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
Data ReadoutpositiveRentosertibPositive
AI Analysis
Summary
Insilico Medicine's rentosertib, the first drug designed with generative AI for a de-novo AI-discovered target, demonstrated potential for biological age reversal in IPF based on assessment by six proteomic aging clocks. This represents the first evaluation of an AI-driven candidate using consensus aging clock biomarkers.
Clinical Trial Data
Outcome Details
AI-driven IPF candidate shows potential for biological age reversal as assessed by six proteomic aging clocks
Importance:6/10
Sentiment:
0.70
AI-driven drug discoveryaging clocksproteomic biomarkersIPFfirst-in-classde-novo target
Read the original article
Published by PR Newswire Clinical Trials on September 7, 2026 9:42 AM